AIMMUNE THERAPEUTICS INC's ticker is AIMT and the CUSIP is 00900T107. A total of 193 filers reported holding AIMMUNE THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 1.23 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $99,000 | +106.2% | 2,879 | 0.0% | 0.00% | – |
| Q2 2020 | $48,000 | +14.3% | 2,879 | 0.0% | 0.00% | – |
| Q1 2020 | $42,000 | -56.2% | 2,879 | 0.0% | 0.00% | – |
| Q4 2019 | $96,000 | -15.0% | 2,879 | -46.9% | 0.00% | – |
| Q2 2019 | $113,000 | -6.6% | 5,426 | 0.0% | 0.00% | – |
| Q1 2019 | $121,000 | +59.2% | 5,426 | +63.7% | 0.00% | – |
| Q4 2018 | $76,000 | -16.5% | 3,315 | 0.0% | 0.00% | – |
| Q3 2018 | $91,000 | +2.2% | 3,315 | 0.0% | 0.00% | – |
| Q2 2018 | $89,000 | -16.0% | 3,315 | 0.0% | 0.00% | – |
| Q1 2018 | $106,000 | -15.2% | 3,315 | 0.0% | 0.00% | – |
| Q4 2017 | $125,000 | +54.3% | 3,315 | 0.0% | 0.00% | – |
| Q3 2017 | $81,000 | +19.1% | 3,315 | 0.0% | 0.00% | – |
| Q2 2017 | $68,000 | -5.6% | 3,315 | 0.0% | 0.00% | – |
| Q1 2017 | $72,000 | +5.9% | 3,315 | 0.0% | 0.00% | – |
| Q4 2016 | $68,000 | – | 3,315 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management II, LLC | 3,100,146 | $117,248,000 | 40.96% |
| TLP GROUP LLC | 1,050,000 | $39,711,000 | 27.53% |
| Aisling Capital LLC | 2,240,000 | $84,717,000 | 16.74% |
| Foresite Capital Management III, LLC | 764,824 | $28,926,000 | 8.12% |
| AlpInvest Partners B.V. | 51,498 | $1,948,000 | 6.95% |
| Vivo Capital, LLC | 643,626 | $24,342,000 | 5.21% |
| GREAT POINT PARTNERS LLC | 573,550 | $21,692,000 | 3.70% |
| Eventide Asset Management | 1,226,000 | $46,367,000 | 2.42% |
| Palo Alto Investors LP | 1,146,419 | $43,358,000 | 1.87% |
| HAMILTON LANE ADVISORS LLC | 78,846 | $2,982,000 | 1.54% |